<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303156</url>
  </required_header>
  <id_info>
    <org_study_id>8591-026</org_study_id>
    <secondary_id>2020-000153-27</secondary_id>
    <secondary_id>MK-8591-026</secondary_id>
    <nct_id>NCT04303156</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)</brief_title>
  <official_title>An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Islatravir (MK-8591) in Subjects With Severe Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the general tolerability and pharmacokinetics (PK) of a single 60 mg
      dose of Islatravir in participants with severe renal insufficiency, compared to participants
      in good health.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2020</start_date>
  <completion_date type="Anticipated">December 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve from time 0 to infinity (AUC0-inf) of plasma islatravir (ISL)</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
    <description>Area Under the Curve from time 0 to infinity (AUC0-inf) of plasma islatravir (ISL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve from time 0 to last sampling time (AUC0-last) of plasma ISL</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
    <description>Area Under the Curve from time 0 to last sampling time (AUC0-last) of plasma ISL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) of plasma ISL</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
    <description>Maximum concentration (Cmax) of plasma ISL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum concentration (Tmax) of plasma ISL</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
    <description>Time of maximum concentration (Tmax) of plasma ISL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal half-life (t1/2) of plasma ISL</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
    <description>Apparent terminal half-life (t1/2) of plasma ISL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance (CL/F) of plasma ISL</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
    <description>Apparent clearance (CL/F) of plasma ISL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F) of plasma ISL</measure>
    <time_frame>Pre-dose, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 168 hours post-dose</time_frame>
    <description>Apparent volume of distribution (Vz/F) of plasma ISL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-inf of ISL triphosphate (ISL-TP) in peripheral blood mononuclear cells (PBMC)</measure>
    <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
    <description>AUC0-inf of ISL triphosphate (ISL-TP) in peripheral blood mononuclear cells (PBMC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-last of ISL-TP in PBMC</measure>
    <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
    <description>AUC0-last of ISL-TP in PBMC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of ISL-TP in PBMC</measure>
    <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
    <description>Cmax of ISL-TP in PBMC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of ISL-TP in PBMC</measure>
    <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
    <description>Tmax of ISL-TP in PBMC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 24 hours post dose (C24) of ISL-TP in PBMC</measure>
    <time_frame>24 hours post-dose</time_frame>
    <description>Concentration at 24 hours post dose (C24) of ISL-TP in PBMC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 168 hours post dose (C168) of ISL-TP in PBMC</measure>
    <time_frame>168 hours post-dose</time_frame>
    <description>Concentration at 168 hours post dose (C168) of ISL-TP in PBMC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 672 hours post dose (C672) of ISL-TP in PBMC</measure>
    <time_frame>672 hours post-dose</time_frame>
    <description>Concentration at 672 hours post dose (C672) of ISL-TP in PBMC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2 of ISL-TP in PBMC</measure>
    <time_frame>Pre-dose, 4, 24, 48, 96, 168 hours post-dose</time_frame>
    <description>T1/2 of ISL-TP in PBMC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants with an Adverse Event (AE)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>Percentage of participants with an Adverse Event (AE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants who discontinued from the study due to an AE</measure>
    <time_frame>Day 1</time_frame>
    <description>Percentage of participants who discontinued from the study due to an AE</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Human Immunodeficiency Virus (HIV) Infection</condition>
  <arm_group>
    <arm_group_label>Islatravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 60 mg Islatravir (MK-8591)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Islatravir</intervention_name>
    <description>Single oral dose of 60 mg Islatravir administered in capsule form</description>
    <arm_group_label>Islatravir</arm_group_label>
    <other_name>MK-8591</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy participants must have the following:

          -  Is in good health

          -  Has a body mass index (BMI) ≥18.5 and ≤40 kg/m2.

          -  Female is not pregnant or breastfeeding, and is not one of the following: a woman of
             childbearing potential (WOCBP); if a WOCBP, is using an acceptable contraceptive
             method, or is abstinent from heterosexual intercourse as their preferred and usual
             lifestyle; a WOCBP must have a negative highly sensitive pregnancy test within 24
             hours before the first dose of study intervention

        Renally impaired participants must have the following:

          -  With the exception of renal impairment, is in generally good health

          -  Has a BMI ≥ 18.5 and ≤ 40 kg/m2

          -  Female is not pregnant or breastfeeding, and is not one of the following: a woman of
             childbearing potential (WOCBP); if a WOCBP, is using an acceptable contraceptive
             method, or is abstinent from heterosexual intercourse as their preferred and usual
             lifestyle; a WOCBP must have a negative highly sensitive pregnancy test within 24
             hours before the first dose of study intervention

        Exclusion Criteria:

        Healthy participants must have the following:

          -  Has a history of clinically significant endocrine, gastrointestinal, cardiovascular,
             hematological, hepatic, immunological, renal, respiratory, genitourinary, or major
             neurological (including stroke and chronic seizures) abnormalities or diseases.

          -  Is mentally or legally incapacitated, has significant emotional problems

          -  Has known hypersensitivity to the active substance or any of the excipients of the
             study drug

          -  Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex
             allergy), or has had an anaphylactic reaction or significant intolerability (i.e.
             systemic allergic reaction) to prescription or non-prescription drugs or food.

          -  Is positive for hepatitis B surface antigen, hepatitis C antibodies or HIV.

          -  Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within prior
             4 weeks

          -  Is taking medications to treat chronic medical conditions and/or conditions associated
             with renal disease

          -  Has participated in another investigational study within prior 4 weeks

        Other exclusions for healthy participants:

          -  Does not agree to follow the smoking restrictions

          -  Consumes greater than 1 glass for women, or 2 glasses for men of alcoholic beverages
             per day

          -  Consumes excessive amounts,of caffeinated beverages per day.

          -  Is a regular user of cannabis, any illicit drugs or has a history of drug (including
             alcohol) abuse within approximately prior 3 months.

        Renally impaired participants must have the following:

          -  Has a history or presence of renal artery stenosis.

          -  Has had a renal transplant or nephrectomy.

          -  Has rapidly fluctuating renal function as determined by historical measurements.

          -  Has known hypersensitivity to the active substance or any of the excipients of the
             study drug.

          -  Has a history of cancer (malignancy).

          -  Has a history of significant multiple and/or severe allergies (e.g. food, drug, latex
             allergy), or has had an anaphylactic reaction or significant intolerability (i.e.
             systemic allergic reaction) to prescription or non-prescription drugs or food.

          -  Is positive for hepatitis B surface antigen, hepatitis C antibodies or human
             immunodeficiency virus (HIV).

          -  Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4
             weeks prior to the prestudy (screening) visit.

          -  Is taking medications to treat chronic medical conditions and/or conditions associated
             with renal disease and has not been on a stable regimen for at least 1 month and/or is
             unable to withhold the use of the medication(s) within 4 hours prior to and 8 hours
             after administration of the study drug.

          -  Has participated in another investigational study within 4 weeks (or 5 half-lives,
             whichever is greater) prior to the prestudy (screening) visit.

        Other exclusions for renally impaired participants

          -  Does not agree to follow the smoking restrictions.

          -  Consumes greater than 1 glass for women, or 2 glasses for men of alcoholic beverages
             per day.

          -  Consumes excessive amounts of caffeinated beverages per day.

          -  Is a regular user of cannabis, any illicit drugs or has a history of drug (including
             alcohol) abuse within approximately 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami ( Site 0001)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-620-7002</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4'-ethynyl-2-fluoro-2'-deoxyadenosine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

